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Brief Report
ABSTRACT
Indoleamine 2,3-dioxygenase degrades the amino acid tryptophan which is essential for T cells. Tryptophan depletion causes T-cell cycle
arrest and solid tumors that express high levels of indoleamine 2,3-dioxygenase can create immune suppression. Recently, blasts of
patients with acute myeloid leukemia were shown to express indoleamine 2,3-dioxygenase. We determined INDO (encoding gene for
indoleamine 2,3-dioxygenase) mRNA expression in leukemic blasts of 286 patients with acute myeloid leukemia by gene-expression pro-
filing. Results were validated by quantitative polymerase chain reaction analysis in blasts of an independent cohort of 71 patients. High
INDO expression was correlated to significantly shortened overall and relapse-free survival. Correlation of INDO expression to relevant
known prognostic factors and survival identified high INDO expression as a strong negative independent predicting variable for overall
and relapse-free survival. Inhibition of indoleamine 2,3-dioxygenase expressed by myeloid leukemic blasts may result in breaking
immune tolerance and offers new therapeutic options for patients with acute myeloid leukemia.
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Introduction 
Successful immunotherapy requires not only the develop-
ment of effector T cells, but also the break-through of the
local state of immune tolerance that tumors can create.
Besides several cellular and soluble factors (like the presence
of regulatory T cells and transforming growth factor β),1 over-
expression of the enzyme indoleamine 2,3-dioxygenase can
induce tolerance. Indoleamine 2,3-dioxygenase degrades the
essential amino acid tryptophan into kynurenine. High levels
of indoleamine 2,3-dioxygenase result in immune suppression
because T cells undergo cell cycle arrest in G1 phase at low
tryptophan levels.2 Moreover, kynurenine and its derivates are
directly toxic for T cells.3 Biologically relevant indoleamine
2,3-dioxygenase to limit T-cell activation4 is expressed by
interferon-α stimulated antigen presenting cells, in lower
intestinal epithelial cells in which non-pathogenic bacteria are
frequently present, and in trophoblast cells in which it pro-
tects the fetus from attack by maternal cytotoxic T cells.5
Tumor induced overexpression of indoleamine 2,3-dioxyge-
nase causes immune-suppression at two levels. First, inhibi-
tion of effective T-cell priming by antigen presenting cell
derived indoleamine 2,3-dioxygenase has been demonstrated
in tumor-draining lymph nodes.6 Second, the effector phase of
an anti-tumor immune response is hampered because many
human solid tumors themselves express indoleamine 2,3-
dioxygenase.7-9
In acute myeloid leukemia, acquired mutations of the
hematopoietic stem cells block differentiation. The result is
accumulation of immature cells in the bone marrow and
peripheral blood, often accompanied by suppression of the
normal blood cells. With chemotherapy and stem cell trans-
plantation about 70% of patients achieve complete remission
but approximately half of these patients relapse from the sta-
tus of minimal residual disease.10 The immune system as sur-
veillant in acute myeloid leukemia is unlikely to play a role at
the moment of diagnosis (when an enormous tumor burden
exists) but this is more likely during the period of minimal
residual disease (when the patient has achieved morphologi-
cal complete remission). We hypothesize that, in this phase of
the disease, overexpression of indoleamine 2,3-dioxygenase
by myeloid leukemic blasts could hamper immunesurveil-
lance resulting in immune escape and shortened relapse-free
and overall survival. With regard to hematologic malignan-
cies, Curti et al. reported active indoleamine 2,3-dioxygenase
protein in 52% of acute myeloid leukemic samples.11 They
also clearly demonstrated that indoleamine 2,3-dioxy-
genase expressed by human myeloid leukemic cells
induces the expansion of CD4+CD25+FOXP3+ regulato-
ry T cells in mice.12 These data presume an important
role for indoleamine 2,3-dioxygenase in immune
escape. However, negative influence of high
indoleamine 2,3-dioxygenase expression on overall sur-
vival of patients has only been demonstrated for
endometrial and colorectal cancer.8,9 In the present study
we investigated whether the expression of INDO (the
gene encoding for indoleamine 2,3-dioxygenase) corre-
lates to clinical outcome of patients with acute myeloid
leukemia. We determined INDO expression in myeloid
leukemic blasts of 285 patients by gene-expression
analyses and in 71 patients by real-time quantitative
polymerase chain reaction (qPCR) and correlated these
data to relevant known prognostic factors and survival. 
Design and Methods
Patients’ characteristics
After informed consent and according to the recom-
mendations as defined in the declaration of Helsinki in
1989, bone marrow derived samples were collected
from patients with primary acute myeloid leukemia.
Patients were classified according to the French-
American-British (FAB) classification.13 Clinical charac-
teristics of the patients that were selected for gene-
expression profiling analysis have been previously
described14 and shown in Table 1. For patients analyzed
by qPCR, clinical characteristics are comparable to the
clinical characteristics of patients that were analyzed by
gene-expression profiling (Table 1). 
Cytogenetic risk group was defined as favorable
(t(8;21), inv(16) or t(15;17)), standard (neither favorable
nor adverse) or adverse (complex karyotype, -5, -7,
del(5q), del(7q), abn (3q), t(6;9) or abn (11q23)).
Patients of both groups received therapy according to
HOVON (Dutch-Belgian Hematology-Oncology Co-
operative Group) protocols. Most patients received 2
cycles of chemotherapy (containing cytarabin combined
with idarubicin or amsacrine) followed by an autolo-
gous stem cell transplantation or a third cycle of
chemotherapy (mitoxantrone and etoposide). Only 3
patients received allogeneic stem cell transplantation.
Protocols are available at www.hovon.nl. Overall survival
was defined as the time period from inclusion to death
or last date of follow-up; relapse-free survival was
defined as the time period from achievement of com-
plete remission to relapse. 
Sample characteristics
Blood and bone marrow derived mononuclear cell
fractions from patients with primary acute myeloid
leukemia were obtained by Ficoll centrifugation (purity
of blasts >80%), cryopreserved and used for gene-
expression profiling. For qPCR analysis, 7AAD–/An-
nexinV–/CD45dim cells from patients with primary acute
myeloid leukemia were FACS sorted after thawing
(purity of blasts >95%). For comparison, bone marrow
from 5 healthy donors was withdrawn and 7AAD–/An-
nexinV–/CD45dim normal blasts (purity >95%) were
FACS sorted. 
Gene-expression profiling and real-time qPCR
Gene-expression levels for INDO were determined by
using Affymetrix U133A GeneChips14 (Affymetrix-id for
INDO 210029_at, M34455 NCBI). For qPCR, RNA was
isolated using RNA-Bee solution (Tel-Test Inc,
Friendswood, TX, USA). Total RNA was stored at -80°C.
cDNA synthesis was performed according to a stan-
dardized Europe Against Cancer protocol.15 PCR ampli-
fication was performed with a LightCycler real-time
PCR machine (Roche Diagnostics, Almere, the
Netherlands). Reaction volumes were 20 µL, consisting
of 2 µL cDNA, 2 µL of LightCycler Fast Start DNA SYBR
Green Mastermix (Roche) and 0.5 µM reverse and for-
ward primers. MgCl2 was added to a final concentration
of 3.5 µM (for GUS 4 µM). qPCR conditions consisted
of an initial denaturation step at 95ºC for 10 min, fol-
lowed by 45 cycles, each for 15 sec at 95ºC, 10 sec at
58ºC (for GUS 59ºC) and 10 sec at 72ºC. Relative quan-
titation of gene-expression was determined using the
LB1610 cell line (see Acknowledgments). All results were
normalized with respect to the β-glucuronidase (GUS)
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Table 1. Comparison of clinical characteristics of patients with
acute myeloid leukemia whose blasts were analyzed for INDO
expression by gene-expression profiling and by qPCR. 
Type of analysis Gene-expression profiling qPCR
Number 286 71
Median age in years 44 (15-78) 54 (16-75)
at diagnosis (range)
Median white blood cell count 28 (0.3-582) 42 (0.4-282)
at diagnosis (10×9/L, range)
Complete remission rate, 203 (79.6) 55 (78)
number (%)
Median overall survival 13 (0-166) 14.4 (0.03-174)
in months (range)
Median relapse free survival 11 (0-166) 16.6 (0.23-173)
in months (range)
FAB classification, number (%)
AML M0 6 (2) 4 (6)
AML M1 63 (22) 9 (13)
AML M2 66 (23) 20 (19)
AML M3 19 (7) 3 (4)
AML M4 53 (19) 12 (17)
AML M5 65 (23) 20 (28)
AML M6 3 (1) 3 (4)
not determined 10 (3)
Cytogenetic risk group, number (%)
Favorable 57 (20) 4 (6)
Standard 176 (62) 40 (56)
Adverse 39 (14) 6(9)
No metaphasis 13 (4) 6 (9)
Not done 15 (21)
FLT3 status, number (%)
FLT3 ITD pos 78 (27) 19 (27)
FLT3 ITD neg 207 (73) 52 (73)
FLT3 TKD pos 33 (12) 5 (7)
FLT3 TKD neg 252 (88) 66 (93)
control. Primer sequences were: INDO forward: 5’-
GTGTTTCACCAAATCCACGA-3’, reverse: 5’-CTG-
ATAGCTGGGGGTTGC-3’; GUS forward: 5’-GAA-
AATATGTGGTTGGAGAGCTCATT-3’, reverse: 5’-
CCGAGTGAAGATCCCCTTTTTA-3 (Biolegio BV,
(Nijmegen, the Netherlands).
Western blot
For Western Blot analysis, human peripheral blood
derived monocytes selected by magnetic separation
(positive selection with CD14 microbeads, Miltenyi
Biotec, Bergisch Gladbach, Germany) were used. Purity
was greater than 97%. Monocytes were incubated for
18 hours with interferon-α. Snap frozen cells were pre-
pared by resuspending in lysis buffer (50 mM Tris-HCl
(pH 7.6), 5 mM dithiotreitol, 20 µL PIC (Protease
Inhibitor Cocktail; 1 tablet/mL H2O), 20% glycerol and
0.5% NP-40). Protein content of the supernatant was
determined by the Bio-Rad protein assay. Twenty
micrograms of total cell lysates were fractionated on a
12.5% polyacrylamide gel containing SDS and trans-
ferred onto a PVDF membrane. Indoleamine 2,3-dioxy-
genase was visualized by luminescence (ECL Kit,
Amersham) using Hyperfilm ECL (Amersham) after
incubation with anti-human indoleamine 2,3-dioxyge-
nase antibody (clone 10.1, Chemicon, 1:1000) and
horseradish peroxidase–coupled rabbit anti-mouse IgG.
α-tubulin was detected by incubation with a mouse
anti-human α-tubulin monoclonal antibody (Sc-5286
Santa Cruz) by luminescence as above.
Statistical analysis
Statistical analyses were conducted using a SPSS
12.0.1 software program. To determine associations
between variables, Spearman’s correlation coefficient
was used. Differences between patients’ characteristics
were analyzed with the Mann-Whitney U test. For  sur-
vival data, Kaplan-Meier curves were compared by
means of the log-rank test. To explore the simultaneous
effect of several variables on overall and relapse-free
survival the Cox regression model was used.
Results and Discussion
Two hundred and eighty-six patients were analyzed
for the expression of INDO by gene-expression profil-
ing. INDO mRNA expression was variable and not sig-
nificantly associated with any one of the 16 subtypes of
acute myeloid leukemia, which were identified on their
specific gene-expression signatures,14 presuming inde-
pendency of these prognostic clusters (Figure 1A).
Moreover, no significant differences were found
between INDO mRNA expression of different FAB sub-
types and cytogenetic risk profiles. Correlation of INDO
expression to survival data of 262 patients revealed that
all patients with prolonged overall survival had low
INDO expression. We decided to validate these data by
qPCR. Correlation between microarray and qPCR is
generally strong, although there is non-concordance in
13-16% of genes.16 INDO mRNA expression levels rela-
tive to GUS by qPCR nicely correlated to protein levels
as determined by Western blot on human peripheral
blood interferon-α stimulated monocytes (Figure 1B).
We then determined INDO mRNA expression levels in
71 patients and 5 healthy donors. INDO expression rel-
ative to GUS in blasts of healthy donors was low (mean
0.538, median 0.32, range 0.06-1.18). INDO expression
relative to GUS in blasts of patients with acute myeloid
leukemia was highly variable, but mean and median
expression was higher (mean 5.68, median 0.51, range
0-304) than INDO expression in blasts of healthy
donors.
As in the patient group analyzed by gene-expression
profiling, no significant differences in INDO expression
analyzed by qPCR were found between FAB subtypes
and cytogenetic risk groups. As the white blood cell
count in this patient group was high (median 42×109/L)
and FLT3 (fms-related tyrosine kinase 3) mutations are
frequently found in patients with a high white blood
cell count, we also analyzed FLT3 internal tandem dupli-
cation (ITD) and tyrosine kinase domain (TKD) muta-
tions, but INDO expression was not significantly differ-
ent in patients with the mutations of FLT3 (mean INDO
expression: FLT3-ITD positive patients 11.5, FLT3-ITD
negative patients 11.6). 
When correlating INDO expression levels to clinical
outcome, patients with prolonged overall survival had
low INDO levels (Figure 1C). As the maximum INDO
level in healthy donors was 1.2 relative to GUS, we
divided the patients into 2 groups; those having INDO
greater than 1.2 (n=15) or lower than or equal to 1.2
(n=56). There was no difference in median age and
white blood cell counts at diagnosis between these
groups. However, patients with INDO level > 1.2 had a
significantly decreased overall survival as compared to
patients with INDO level lower than 1.2 [7.4 months vs.
21.4 months respectively, p=0.01 (Mann-Whitney U)].
Also, relapse-free survival was significantly shortened in
patients with INDO level gretear than 1.2 as compared
to patients with INDO level lower than 1.2 (6.1 months
vs. 24.5 months respectively, p=0.025 (Mann-Whitney
U)). Note that other cut-off levels such as 0.5 (median of
healthy controls) or 1.5 resulted in comparable signifi-
cant results. INDO expression more or less than 1.2
resulted in strongly diverging Kaplan Meier survival
curves for overall and relapse-free survival (Figures 1D
and 1E). 
In a univariate regression model, INDO expression
level greater than 1.2 was the strongest predictor for
overall survival (p<0.001 odds ratio 3.2), as compared to
white blood cell count (p=0.038, odds ratio 1.004), age
(p=0.012, odds ratio 1.019) and FLT3-ITD mutation
(p=0.058, odds ratio 1.8). In a multivariate regression
model with the same variables, INDO expression level
greater than 1.2 remained the strongest independent
factor predicting survival (p=0.001 vs. p=0.29 (white
blood cell count), p=0.005 (age) and p=0.055 (FLT3-ITD
mutation).
As the groups of patients with good and poor cytoge-
netic risk profile were too small to use in a multiple
regression model, the group with an intermediate cyto-
genetic risk profile was analyzed (n=40). Also in this
group INDO expression was a strong predictor for sur-
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vival (p=0.009, odds ratio 1.146). Myeloid leukemic
blasts do express an active form of indoleamine 2,3-
dioxygenase protein as previously demonstrated in
human myeloid leukemic samples and in vivo in mice.11,12
Moreover, Curti et al. demonstrated good correlation
between INDO mRNA level, indoleamine 2,3-dioxyge-
nase protein expression levels and function in myeloid
leukemic samples. 
Our findings show that all patients with prolonged
overall survival had low INDO expression levels and
that high INDO expression levels were a strong nega-
tive predicting variable for worse outcome of patients
with acute myeloid leukemia. In a multivariate regres-
sion model, a high INDO expression level was a
stronger predicting variable than white blood cell count,
age and FLT3-ITD mutational status. 
High INDO expression was also significantly correlat-
ed to a lower complete remission rate (53% for patients
with INDO expression level greater than 1.2 (p=0.01
(Mann-Whitney U) versus 84% for patients with INDO
expression level lower than 1.2, p=0.01 (Mann-Whitney
U)). This was surprising as it is not expected that the
amount of indoleamine 2,3-dioxygenase in blasts is
affecting drug sensitivity. In this study, we cannot
exclude that high INDO expression is a part of a more
complex phenotype associated with chemoresistance.
However, when only analyzing patients that achieved
complete remission, high INDO expression was corre-
lated to shortened relapse-free survival. 
In the treatment of patients with acute myeloid
leukemia, there is a need for additional therapies to pre-
vent relapse in patients that have achieved complete
remission. The success of allogeneic stem cell transplan-
tation has demonstrated clearly that immune surveil-
lance plays a role by eradicating minimal residual
leukemic cells resulting in prolonged complete remis-
sion rates for patients with acute myeloid leukemia.
However, allogeneic stem cell transplantation is not
available for many patients. For these patients, rehabili-
tation of autologous immune surveillance, for example
INDO mRNA expression in myeloid leukemic blasts
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Figure 1. (A) INDO expression by microar-
ray and by qPCR correlated to clinical
outcome. Unsupervised cluster analyses
on the basis of gene-expression profiles
of 285 blasts of patients with acute
myeloid leukemia. The columns adjacent
to the heatmap indicate sample charac-
teristics (column 1: the 16 gene-expres-
sion cluster (distinct colors 1-16); col-
umn 2: FAB (M0-red, M1-green, M2-pur-
ple, M3-orange, M4-yellow, M5-blue, M6-
grey); column 3: karyotype (normal-
green, inv(16)-yellow, t(8;21)-purple,
t(15;17)-orange, 11q23 abnormalities-
blue, 7(q) abnormalities-red, +8-pink,
complex-black, other-gray)); column 4:
INDO mRNA expression (probe set ID
210029_at, size of histogram propor-
tional to level of expression). INDO
expression does not correlate to one of
the 16 previously described gene-expres-
sion subgroups,14 the FAB classification
or karyotype of the acute myeloid
leukemia cases. (B) INDO mRNA expres-
sion levels (relative to GUS) by qPCR
nicely correlated to protein levels of
indoleamine 2,3-dioxygenase (IDO) as
determined by Western Blot on human
peripheral blood interferon-γ (IFN-γ) stim-
ulated monocytes. (C) INDO expression
analyzed by qPCR in 71 patients with
acute myeloid leukemia. Patients with
prolonged overall survival have low INDO
expression level. D. and E. INDO expres-
sion levels analyzed by qPCR; INDO
expression >1.2 (relative to GUS) corre-
lates to significantly shortened overall
and relapse-free survival (x- axis is log
transformed). 
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by inhibition of tumor induced indoleamine 2,3-dioxy-
genase expression could offer new treatment possibili-
ties. As inhibition of indoleamine 2,3-dioxygenase by
orally available inhibitors like 1-methyl–tryptophan is
effective in mice and synergistic with chemotherapy,17,18
we now provide further reason for rapid exploration of
the introduction of indoleamine 2,3-dioxygenase inhibi-
tion in the treatment of patients with acute myeloid
leukemia. Besides these opportunities for new immune
modulating therapies, measuring INDO levels provides
useful prognostic information, as a high INDO expres-
sion level is correlated to a lower complete remission
rate, and shorter overall and relapse-free survival of
patients with acute myeloid leukemia.
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